

TABLE E-1 Modified Charnley Pain Score for Evaluating Self-Reported Hip Pain²⁷

Score	Pain Category
0	No pain
1	Pain is slight or intermittent, pain on starting to walk but getting less with normal activity
2	Pain occurs only after some activity, disappears quickly with rest
3	Pain is tolerable, permitting limited activity
4	Pain is severe on attempting to walk, prevents all activity
5	Pain is severe and spontaneous

TABLE E-2 Details of Surgical Implants*

	Teriparatide (N = 86)	Risedronate (N = 85)	Total (N = 171)
Sliding hip screw system† (no. [%])	33 (100)	41 (100)	74 (100)
Type			
Dynamic hip screw system	27 (81.8)	35 (85.4)	62 (83.8)
Compression hip screw	6 (18.2)	4 (9.8)	10 (13.5)
Other	0	2 (4.9)	2 (2.7)
No. of lag screws (no. [%])			
1	33 (100)	37 (92.5)	70 (95.9)
2	0	3 (7.5)	3 (4.1)
Not known	0	1 (2.4)	1 (1.4)
Lag screw diameter‡§ (no. [%])			
6-10 mm	19 (57.6)	30 (73.2)	49 (66.2)
11-15 mm	14 (42.4)	11 (26.8)	25 (33.8)
Trochanteric nail system§ (no. [%])	53 (100)	44 (100)	97 (100)
Type			
ENDOVIS intramedullary nail (Citieffe)	12 (22.6)	10 (22.4)	22 (22.7)
Trochanteric gamma nail (3rd generation) (Stryker)	11 (20.8)	8 (18.2)	19 (19.6)
Trochanteric gamma nail (2nd generation) (Stryker)	3 (5.7)	3 (6.8)	6 (6.2)
Trochanteric fixation nail (Synthes)	6 (11.3)	9 (20.5)	15 (15.5)
Proximal femoral nail (Synthes)	10 (18.9)	5 (11.4)	15 (15.5)
Veronail trochanteric system (Orthofix)	5 (9.4)	3 (6.8)	8 (8.2)
Intramedullary hip screw (Smith & Nephew)	0 (0.0)	3 (6.8)	3 (3.1)
Other	6 (11.3%)	3 (6.8%)	9 (9.2%)
Nail length, median (IQR) (mm)	200 (180-240)	200 (180-215)	200 (180-240)
Nail length§ (no. [%])			
<120 mm	2 (3.8)	3 (7.0)	5 (5.2)
120-250 mm	49 (92.5)	36 (83.7)	85 (88.5)
251-400 mm	2 (3.8)	4 (9.3)	6 (6.3)
Not known	0	1 (2.3)	1 (1.0)

*Percentages are based on number of patients with non-missing values. IQR = interquartile range. †Percentages are based on the total number of patients implanted with a sliding hip screw system. ‡§If there were 2 lag screws with different diameters, the diameter of the top screw was used in the analysis. §Percentages are based on the total number of patients implanted with a trochanteric nail.

TABLE E-3 Assessment of Functional Mobility by Time to Complete the Timed Up-and-Go Test*

	LS Means (SE)†	P Value	95% CI
Overall	0.83 (1.08)	0.021	0.71 to 0.97
Week 6	0.82 (1.09)	0.029	0.69 to 0.98
Week 12	0.82 (1.09)	0.026	0.69 to 0.98
Week 18	0.85 (1.09)	0.074	0.71 to 1.02
Week 26	0.84 (1.09)	0.058	0.71 to 1.01

*MMRM (mixed-effects model for repeated measures) analysis of log-transformed time. Variables in the full model included treatment, visit, treatment-visit interaction, age, type of fracture, type of reduction, type of walking aid, SF-36 physical component score, and baseline Charnley hip pain score. LS = least squares, SE = standard error, and CI = confidence interval.

†Treatment difference between groups, expressed as the ratio of the teriparatide group to the risedronate group (back-transformed log differences). The total number of patients who contributed to the MMRM was 157 (79 teriparatide, 78 risedronate).

TABLE E-4 Evaluation of Self-Reported Hip Pain During the Timed Up-and-Go Test by 100-mm VAS*

	LS Means (SE)† (<i>mm</i>)	95% CI (<i>mm</i>)	P Value
Overall	-10.33 (4.80)	-19.77 to -0.90	0.032
Week 6	-8.65 (5.26)	-19.01 to 1.70	0.101
Week 12	-10.60 (5.18)	-20.78 to -0.41	0.041
Week 18	-11.93 (5.23)	-22.22 to -1.64	0.023
Week 26	-10.15 (5.25)	-20.47 to 0.17	0.054

*MMRM (mixed-effects model for repeated measures) analysis. Variables in the full model included treatment, visit, treatment-visit interaction, type of fracture, type of reduction, adequacy of reduction, use of opioids, and use of NSAIDs (nonsteroidal anti-inflammatory drugs). LS = least squares, SE = standard error, and CI = confidence interval. †Treatment difference between groups. The total number of patients who contributed to the MMRM was 126 (63 in each treatment arm).

TABLE E-5 Self-Reported Hip Pain by Modified Charnley Pain Score

	Satisfactory* Charnley Hip Pain Score (<i>no.</i> / <i>%</i>)		
	Teriparatide (N = 86)	Risedronate (N = 85)	P Value†
Visit 2 (baseline)‡	12 (14.1)	18 (21.2)	
Week 6	47 (56.0)	52 (62.7)	0.493
Week 12	43 (61.4)	54 (73.0)	0.463
Week 18	51 (79.7)	55 (82.1)	0.361
Week 26	48 (77.4)	58 (87.9)	0.207

*Satisfactory = 0 (no pain) or 1 (pain is slight or intermittent, pain on starting to walk but getting less with normal activity).

†Logistic regression analysis for treatment effect. Full model adjusted by treatment, visit, treatment-visit interaction, type of fracture, type of reduction, use of opioids, and use of NSAIDs (nonsteroidal anti-inflammatory drugs). ‡Randomization visit.